Odyssey Therapeutics, Inc. (ODTX): Results of Operations and Financial Condition
Odyssey Therapeutics, Inc. (ODTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October Phase 2a combination trial of OD-001 with vedoliz
How this was made
The 30-second read
Why it matters
The filing itself is a procedural disclosure that points to the actual earnings content in Exhibit 99.1. Without the exhibit’s figures, the only actionable takeaway is that a new quarterly results package is now available and can be used to reassess valuation, cash runway, and expectations.
Market read
Traders should treat this as the start of the earnings-information window for ODTX, with the real trading signal likely contained in Exhibit 99.1.
What to watch
Traders should focus on cash balance, operating expenses, and any pipeline or financing language in Exhibit 99.1, since those are often the true drivers for biotech 8-K earnings reactions.
Odyssey Therapeutics furnished an 8-K announcing financial results for the three months ended June 30, 2026, but the supplied filing text does not include Exhibit 99.1 or any underlying earnings release financial data.
The filing confirms an earnings announcement but provides no reported operating, financial, liquidity, capital-return, or guidance figures in the supplied text.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|
Concerns
- Exhibit 99.1, identified as the press release dated August 4, 2026, is not included in the supplied filing text.
- No revenue, expense, earnings, cash-flow, liquidity, balance-sheet, clinical-program, or guidance disclosure is available in the supplied text.
What to watch
- The contents of Exhibit 99.1, including financial statements, cash runway commentary, operating expenses, and any development-program updates.
- Any forward-looking financial or clinical guidance contained in the omitted earnings press release.
Analysis
Odyssey Therapeutics furnished its Form 8-K under Item 2.02 on August 4, 2026 and stated that it announced financial results for the three months ended June 30, 2026. The supplied text identifies Exhibit 99.1 as the related press release dated August 4, 2026, but does not provide that exhibit or reproduce its contents.
As a result, the supplied document contains no reported revenue, research and development expense, general and administrative expense, operating loss, net loss, earnings per share, or non-GAAP measures. There is also no segment disclosure, so demand trends, revenue mix, margins, and changes from the prior year or prior quarter cannot be assessed from this filing text.
The filing does not disclose operating cash flow, free cash flow, cash and equivalents, debt, share repurchases, dividends, or other capital-allocation information. Accordingly, the company's liquidity position and spending profile cannot be evaluated using the available document.
No outlook or guidance is included in the supplied text, and no prior outlook was provided for comparison. The central item for investors is the omitted Exhibit 99.1, which is the only referenced source for the quarter's financial results and any management commentary.
Not in the filing
stated, not guessed- Exhibit 99.1 earnings press release
- Total revenue
- Revenue comparisons and growth rates
- Segment revenue, comparisons, and drivers
- Gross profit and gross margin
- Research and development expense
- General and administrative expense
- Operating expenses
- Operating income or loss
- Net income or loss
- GAAP earnings or loss per share
- Non-GAAP earnings measures
- Operating cash flow
- Free cash flow
- Cash and cash equivalents
- Debt
- Share repurchases
- Dividends
- Forward guidance
- Prior-period guidance for comparison
- Management commentary and named-executive quotes
- Clinical, product, or commercial operating updates
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The SEC Form 8-K (Item 2.02) indicates Odyssey Therapeutics announced quarterly financial results for the three months ended June 30, 2026 and furnished a press release as Exhibit 99.1.
Ticker impact
Odyssey Therapeutics filed an 8-K stating it announced financial results for the three months ended June 30, 2026, with Exhibit 99.1 furnished.
Potentially volatile around the release of Exhibit 99.1 details, but direction depends on the specific results and any guidance included there.
The 8-K itself confirms the results announcement and that the press release is attached as Exhibit 99.1, but the scraped text does not include the actual numbers or guidance.
Market effects
Biopharma small-cap sentiment can shift on quarterly cash burn, runway, and any updates to pipeline milestones, but no such details are present in the scraped text.
Primarily impacts US small-cap biotech sentiment; no cross-market macro linkage is disclosed.
Limited global relevance unless the attached Exhibit 99.1 includes major regulatory or partnership updates, which are not shown here.
Counterpoint
If Exhibit 99.1 contains no material surprises (typical burn and no guidance changes), the filing may have limited incremental impact beyond routine quarterly reporting.
Key entities
- issuerOdyssey Therapeutics, Inc.
Subject of the 8-K, filed to report results of operations and financial condition for the quarter ended June 30, 2026.
- filingSEC Form 8-K
Current report under Item 2.02, furnishing the quarterly results press release as Exhibit 99.1.
